FY2025 · ended Sep 30, 2025 · Revenue $376.57M, +20.3% YoY · Filed Nov 17, 2025
Twist Bioscience Corporation (TWST) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $376.6 million and a net loss of $77.7 million. Free cash flow was -$75.6 million. As of Jun 30, 2026 it held $166.8 million in cash and investments and $93.6 million in total debt.
Revenue (TTM)
$431.80M
+19.2% vs year-ago TTM
Net income (TTM)
$-136.72M
-60.5% vs year-ago TTM
Operating cash flow (TTM)
$-53.07M
-3.8% vs year-ago TTM
Free cash flow (TTM)
$-93.12M
-35.5% vs year-ago TTM
EPS (TTM)
$-2.23
-55.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
61.15M
+3.0% vs prior year
Net cash
$73.25M
as of Jun 30, 2026
Operating margin
-33.6%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TWST (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1581280
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$234.8M | -$152.7M |
| Net income | -$77.7M | -$208.7M | -$204.6M | -$217.9M | -$152.1M |
| Diluted EPS | -$1.30 | -$3.60 | -$3.60 | -$4.04 | — |
| Operating cash flow | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M |
| Free cash flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M | -$139.3M |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M | $702.1M |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M | $121.3M |
| Stockholders' equity | $473.0M | $472.7M | $623.4M | $789.4M | $580.8M |
| Cash and investments | $232.4M | $276.4M | $336.4M | $505.0M | $477.9M |
| Total debt | $75.6M | $85.0M | $94.1M | $94.9M | $62.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 19, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 19, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 5, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
All 1001 Twist Bioscience Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.